Adenoma - 647 Studies Found

Recruiting : 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
: Gastro-entero-pancreatic Neuroendocrine Tumors
: 2016-04-07
:
  • Drug: Capecitabine oral low do
Not yet recruiting : Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib
: Pancreatic Neuroendocrine Tumour Metastatic
: 2016-03-16
: Drug: Sunitinib Sunitinib 37.5 mg/day
Not yet recruiting : Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival
: Pancreatic Neuroendocrine Tumor
: 2015-11-30
: Procedure: pancreatectomy Remove the pancreatic neuroendocrine tumor by surgery
Recruiting : Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
: Neuroendocrine Tumors
: 2015-10-26
:
  • Drug: Sulfatinib Sulfatinib 30
Recruiting : Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
:
  • Carcinoid Tumors
  • Pancreatic NET

: 2015-10-12
: Drug: Ibrutinib Ibrutinib will be administered orally once daily and each cycle will be defined as 4 wee
Recruiting : Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
: Neuroendocrine Tumors
: 2015-06-16
:
  • Drug: 177Lu-DOTATATE 25.9 GBq activity

Completed : An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
: Pancreatic Endocrine Neoplasms
: 2015-03-23
Recruiting : A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
: Pancreatic Neuroendocrine Tumour Metastatic
: 2014-06-17
: Drug: Everolimus 10 mg daily everolimus is a recently approved mTOR inhibitor in advanced progressing we
Recruiting : A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
: 2014-09-23
:
  • Drug: lanreotide Patients will
Recruiting : The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
: Pancreatic Neuroendocrine Tumors
: 2014-10-15
: Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on
<<< Previous | Next >>>